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ABSTRACT
Serum levels of C-reactive protein are (CRP) higher in patients with neoplastic 
conditions and numerous studies have been performed to clarify the etiologic 
and prognostic role of the high-sensitivity CRP (hs-CRP) in cancer. Our study was 
conducted on patients enrolled in the prospective randomized “Italian Trial in 
Advanced Colorectal Cancer (ITACa)” to assess hs-CRP levels and their impact on 
overall survival (OS) and progression-free survival (PFS). Serum samples from 
132 ITACa patients were collected at baseline and 2 months after starting first-line 
chemotherapy. The supernatant was immediately transferred to cryovials and stored 
at –80°C. After thawing, hs-CRP was measured with the Cobas c501 analyzer. High 
levels of hs-CRP (≥ 13.1 mg/L) were associated with poorer median PFS (p < 0.0001) 
and OS (p < 0.0001) than low hs-CRP levels (< 13.1 mg/L). hs-CRP values in 107 
patients were evaluated again after 2 months of therapy, revealing that patients with 
low hs-CRP levels in both baseline and second serum samples had the best median 
PFS and OS. Our study confirms the prognostic value of hs-CRP in patients with 
metastatic colorectal carcinoma.
INTRODUCTION 
Colorectal cancer (CC) is the third most common 
cause of cancer death in Western Europe and North 
America [1]. Interactions between the tumor and the host 
are increasingly recognized as important determinants of 
the clinical course of the disease. In particular, the status 
of the host’s immune system has been shown to be of both 
prognostic and therapeutic relevance in CC and other 
cancers. Beneficial immune responses and detrimental 
pro-inflammatory responses have also been reported [2]. 
A pro-inflammatory immune response to the tumor may 
cause a systemic inflammatory response in the host which 
can be detected in untreated patients before surgery by 
measuring preoperative increases in circulating protein 
levels such as C-reactive protein (CRP) [3].
CRP, a typical systemic inflammation marker, was first 
discovered in the plasma of patients during the acute phase 
of pneumococcal pneumonia [4]. The protein is produced 
almost exclusively in hepatocytes in response to inflammatory 
cytokines, such as interleukin (IL)-1, tumor necrosis factor 
(TNF)-α and, in particular, IL-6 [5, 6]. There is increasing 
evidence that elevated CRP levels are associated with an 
increased risk of malignancy [7–10]. Moreover, elevated CRP 
has been described as a prognostic factor in various tumors, 
including ovarian and gastroesophageal cancer [11–14].
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Some studies have concluded that elevated CRP 
levels are not an independent negative predictor of 
survival [15], whereas others have reported that CRP has 
a prognostic significance in colorectal cancer [16, 17], 
suggesting the presence of a detrimental systemic 
inflammatory response. However, these reports were 
mostly derived from single-center study, analyzing colon 
and rectal cancer together. [17]. 
The correlation between CRP levels and prognosis 
in patients with CRC remains unclear [18, 19]. Several 
studies, including some conducted in non-neoplastic 
pathological settings, have found that an increased IL-6 
expression is often linked to endothelial impairment, 
atherosclerosis and coronary artery disease. Whilst levels of 
CRP seem to be independently associated with a significant 
risk of cardiovascular disease, their role in predicting 
venous thromboembolism (VTE) is still controversial. 
In CC patients, IL-6 has been described as a key 
regulator of cancer development, especially in sporadic 
and inflammation-related tumors [20]. Moreover, in this 
setting, inflammatory cytokines have been described as a 
potential cause of endothelial impairment. Interestingly, 
in experimental models of colitis from inflammatory 
bowel diseases, one study concluded that IL-6 may 
induce a hypercoagulable state through enhanced platelet 
activation [21].
Our study was carried out as a secondary analysis on 
patients enrolled in the phase III prospective multicenter 
randomized “Italian Trial in Advanced Colorectal Cancer 
(ITACa)” (EudraCT no. 2007–004539–44 and registered 
on ClinicalTrials.gov NCT01878422) [22] to assess high-
sensitivity C-reactive protein (hs-CRP) levels at diagnosis 
and their impact on progression-free (PFS) and overall 
survival (OS). A further aim was to evaluate the potential 
role of hs-CRP in predicting a cardiovascular event, in 
particular, venous thromboembolism (VTE).
RESULTS
Patient characteristics
Between 14 November 2007 and 6 March 2012, 
132 patients diagnosed with metastatic colorectal cancer 
were available for baseline hs-CRP analysis (Figure 1): 
78 (59.1%) were males and 54 (40.9%) females with 
a median age at diagnosis of 67 years (range 34–83). 
Median follow-up was 36 months (range 1–65). The main 
demographic and clinical characteristics of the studied 
population are summarized in Table 1. Median PFS was 
9.7 (95% CI 9.0–10.9) and median OS was 22.7 months 
(95% CI 19.3–27.1). 
Figure 1: Flow chart of the study.
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Table 1: Patient characteristics (n = 132)
No. (%)
Median age, years (range) 67 (34–83)
Age
< 70 74 (56.1)
≥ 70 58 (43.9)
Gender
Males 78 (59.1)
Females 54 (40.9)
Performance Status (ECOG)
0 110 (83.3)
1–2 22 (16.7)
Tumor localization
Rectum 37 (28.0)
Colon 95 (72.0)
Stage at diagnosis
I–III 31 (23.5)
IV 101 (76.5)
CT regimen
FOLFOX4 79 (59.8)
FOLFIRI 53 (40.2)
KRAS status
Wild type 75 (59.1)
Mutated 52 (40.9)
Unknown/missing 6
Study treatment
CT + B 67 (50.8)
CT 65 (49.2)
Site of metastases
Only liver 37 (28.0)
Other 95 (72.0)
Comorbidities
Cardiovascular 64 (48.1)
Pulmonary 4 (3.0)
Gastrointestinal/hepatobiliary 10 (7.5)
Metabolic/endocrine 25 (18.8)
Musculoskeletal 4 (3.0)
Dermatologic 1 (0.7)
Reproductive 1 (0.7)
Renal/urinary tracts 3 (2.3)
Allergy 0
Neurologic/psychiatric 22 (16.5)
CT, chemotherapy; B, bevacizumab.
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hs-CRP values and clinical outcome
We evaluated hs-CRP as a continuous variable, 
observing that increased hs-CRP levels were associated 
with decreased PFS (HR = 1.006, 95% CI 1.003–1.009, 
p < 0.0001) and OS (HR = 1.006, 95% CI 1.004–1.009, 
p < 0.0001). ROC curve analysis revealed that the best 
cutoff value of hs-CRP was 13.1 mg/L. 
At baseline, patients with low hs-CRP levels 
(< 13.1 mg/L) had a median PFS of 12.1 months (95% CI 
9.3–14.9) compared to 8.9 months (95% CI 6.8–9.6) for 
those with high hs-CRP levels (≥ 13.1 mg/L, HR = 2.08, 
95% CI 1.43–3.04, p = 0.0001) (Figure 2A). Moreover, 
patients with low baseline hs-CRP had a median OS of 
28.8 months with respect to 14.4 months for those with 
high baseline hs-CRP (HR = 2.79, 95% CI 1.84–4.21, 
p < 0.0001) (Figure 2B). 
Following stratification of patients in the 
2 treatment arms (CT ± bevacizumab) according to 
baseline hs-CRP (< 13.1 mg/L vs. ≥  13.1 mg/L), it 
was observed that PFS and OS were worse when 
hs-CRP was ≥  13.1 mg/L, irrespectively of treatment 
(Figure 3A–3D). Interaction tests involving hs-CRP 
levels and treatment efficacy in the CT + B and CT-only 
groups were not statistically significant for either PFS 
(p = 0.577) or OS (p = 0.108).
Figure 2: Kaplan-Meier curves of progression-free survival (PFS) (A), overall survival (OS) (B) for 132 patients.
Oncotarget10197www.impactjournals.com/oncotarget
We also collected hs-CRP values after 2 months of 
therapy in 107 patients, creating 4 categories according 
to baseline and second-sample hs-CRP levels: low-low, 
low-high, high-low and high-high. The study of dynamic 
hs-CRP levels showed that patients with low-low hs-CRP 
levels had the best median PFS (12.6 months, 95% CI 
10.2–16.0) and OS (29.2 months, 95% CI 25.2–36.7) 
with respect to the other 3 categories (p = 0.002 and 
p = 0.0004 respectively) (Table 2). 
To evaluate hs-CRP modifications during the course 
of chemotherapy and to better understand the role of B in 
such changes, we considered PFS and OS after stratifying 
patients into 2 groups according to hs-CRP levels of the 
second blood sample. The first group included patients 
with low-low and high-low levels of hs-CRP, while 
the second included those with low-high and high-high 
hs-CRP. Patients in the former group had a median PFS of 
11.4 months compared to 8.6 months for those in the latter 
group (HR 1.95, 95% CI 1.19–3.19, p = 0.008). Moreover, 
OS was 25.2 months in the first group and 15.3 months in 
the second group (HR 2.08, 95% CI 1.20–3.62, p = 0.009). 
However, this result was confirmed only in the CT-alone 
arm, where median PFS was 11.3 months in the first group 
and 7.4 months in the second group (HR 2.19, 95% CI 
1.13–4.24, p = 0.02). There were no significant differences 
in PFS or OS between the 2 groups treated with CT plus B 
(Table 3). 
Interestingly, when we evaluated the mean change 
in hs-CRP values between the first and second samples, 
we observed a mean decrease of 10.4 mg/L from 
baseline in the CT plus B group (p = 0.029) and a mean 
decrease of 3.5 mg/L in the CT-alone group (p = 0.089) 
(Figure 4). We also considered drug toxicity as a single 
variable (grade 0–4) or a dichotomous variable (grade 
0–2 vs. grade 3–4) but found no association between 
hs-CRP and toxicity. 
hs-CRP and VTE 
The overall rate of thrombosis was 12.9% (17/132). 
The median baseline level of hs-CRP was 7.7 mg/L 
(range 0.7–301.0) in patients who did not experience 
VTE compared to 13.1 mg/L (range 1.8–301.0) in 
those who did (p = 0.174). The difference was greater, 
Figure 3: Kaplan-Meier curves of PFS in patients treated with chemotherapy plus bevacizumab (A), chemotherapy 
alone (B) and OS in patients treated with chemotherapy plus bevacizumab (C), chemotherapy alone (D).
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albeit not significantly, in the CT + B arm (6.6 mg/L 
in the no VTE group vs. 30.0 mg/L in the VTE group, 
p = 0.149). Evaluation of the mean change in hs-CRP 
values between the first and second samples revealed 
a mean increase of 13.1 mg/L in the thrombosis group 
(p = 0.020) and a mean decrease of 9.6 mg/L in those 
who did not experience a thrombotic event (p = 0.178) 
(Figure 5).
Table 2: PFS and OS: stratification of 107 patients into different groups with respect to hs-CRP 
changes
PFS OS
No. 
patients
No. 
events
Median 
PFS
(95% CI)
p HR (95% CI) p
No. 
events
Median 
OS
(95% CI)
p HR (95% CI) p
Low-Low 58 48 12.6
(10.2–16.0)
1.00 36
29.2
(25.2–36.7)
1.00
Low-High 9 9 7.4
(2.9–10.0)
2.84
(1.37–5.88)
0.005 7
18.2
(3.7–33.1)
2.37
(1.05–5.37)
0.038
High-Low 28 25 9.1
(8.9–11.4)
1.95
(1.18–3.21)
0.009 21
15.0
(13.1–23.3)
2.54
(1.47–4.39)
0.0008
High-High 12 12 9.4
(3.1–15.7)
0.002
2.14
(1.13–4.08)
0.020 10
14.8
(9.0–28.6)
0.0004
3.02
(1.48–6.20)
0.002
Table 3: PFS and OS: stratification of 107 patients in two main groups with respect to hs-CRP 
changes after two months’ therapy
PFS OS
No. 
patients
No. 
events
Median 
PFS
(95% CI)
p HR  (95% CI) p
No. 
events
Median 
OS
(95% CI)
p HR  (95% CI) p
Overall
Low – Low 
+ High  
– Low
86 73
11.4
(9.3–14.0)
1.00 57
25.2
(22.3–29.2)
1.00
Low – High 
+ High  
–High
21 21
8.6
(6.1–10.3)
0.007
1.95
(1.19–3.19)
0.008 17
15.3
(11.5–28.6)
0.008
2.08
(1.20–3.62)
0.009
CT arm
Low – Low 
+ High 
 – Low
40 35
11.3
(9.0–15.0)
1.00 26
27.3
(23.3–36.6)
1.00
Low – High 
+ High  
– High
13 13 7.4
(6.0–10.3)
0.017
2.19
(1.13–4.24)
0.020 12
14.4
(11.6–20.8)
0.0009
3.16
(1.54–6.47)
0.002
CT + B arm
Low – Low 
+ High  
– Low
46 38 11.9
(9.1–14.9)
1.00 31 24.8
(19.3–34.5)
1.00
Low – High 
+ High  
– High
8 8 9.1
(2.9–15.9)
0.204
1.64
(0.76–3.54)
0.210 5
24.5
(3.7-nr)
0.675
1.23
(0.47–3.19)
0.675
nr:not reached.
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DISCUSSION
Elevated levels of CRP have been described as a 
prognostic factor in various human malignancies, including 
tumors of the digestive system. The majority of studies 
assumed that elevated serum CRP levels in patients with 
malignancy constituted a bodily response, secondary to 
tumor necrosis, local tissue damage and inflammation 
caused by cytokines released from leukocytes infiltrating the 
tumor microenvironment, in particular IL-6 [23, 24]. Our 
study showed that high levels of hs-CRP at baseline were 
associated with poorer PFS and OS than low hs-CRP levels.
At present, only one paper has been published 
on the prognostic value of the hs-CRP in patients with 
colorectal cancer [25]. The retrospective study in question 
evaluated a population heterogeneous for clinical stage 
and chemotherapy. We assessed hs-CRP in patients with 
stage IV colorectal cancer at baseline and 2 months after 
beginning chemotherapy. As far as we know, our study 
is the first in the literature to assess the prognostic value 
Figure 5: Mean change in hs-CRP from baseline as a function of venous thromboembolism (VTE).
Figure 4: Mean change in hs-CRP from baseline in chemotherapy plus bevacizumab (CT + B) and chemotherapy 
(CT) arms.
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of hs-CRP in patients with CRC treated with B. All the 
inflammatory conditions unrelated to the tumor that could 
have interfered with the hs-CRP assay were among the 
exclusion criteria of the ITACa trial [22].
Bevacizumab, a recombinant humanised monoclonal 
antibody directed against vascular endothelial growth 
factor (VEGF), was found to improve survival in both first- 
and second-line settings when added to chemotherapy. 
Notably, the results from the present study indicate that 
B is capable of cancelling the negative predictive value 
of high baseline hs-CRP (≥ 13.1 mg/L) that remain high 
after 2 months’ therapy, but also of low baseline hs-CRP 
(< 13.1 mg/L) that increases during the same period of 
treatment. 
One explanation for this could be that increased 
IL-6 levels (and, indirectly, hs-CRP values) are an 
indicator of elevated levels of VEGF [26, 27]. IL-6 
enhances the production of VEGF by fibroblasts, 
thereby inducing angiogenesis [28]. Several studies have 
hypothesized that VEGF may stimulate angiogenesis in 
colon cancer, and this is strongly supported by results 
showing that bevacizumab-induced VEGF inhibition leads 
to decreased angiogenesis and the abrogation of cancer 
growth [22, 29]. 
Inflammation may interfere with various stages of 
hemostasis, either through the activation of coagulation or 
the inhibition of fibrinolysis and anticoagulant pathways 
[30]. As previously reported, the potential correlation 
between hs-CRP values and the risk of thrombosis and 
cardiovascular disease led us to evaluate the incidence of 
VTE in our patients. Although our data failed to confirm that 
hs-CRP is predictive of the risk of thromboembolic events, it 
is noteworthy that hs-CRP values in patients who developed 
thrombosis tended to increase during the course of treatment. 
In conclusion, pre-treatment serum CRP levels may 
constitute a marker of aggressiveness in CRC patients. 
Elevated CRP levels prior to initial treatment would seem 
to be indicative of poor prognosis. 
PATIENTS AND METHODS
The ITACa trial
Our study was conducted on 132 patients enrolled 
in the ITACa trial [22] for whom biological material was 
available. Patients were randomized to receive first-line 
chemotherapy (CT) (FOLFOX4 or FOLFIRI) only or CT 
plus bevacizumab (B). FOLFOX4 consisted of oxaliplatin 
85 mg/m2 as a 2-hour infusion on day 1 and leucovorin 
100 mg/m2 as a 2-hour infusion followed by bolus 5-FU 
400 mg/m2 and a 22-hour infusion of 5-FU 600 mg/m2 on 
days 1–2 every 2 weeks. FOLFIRI consisted of the same 
5-FU + leucovorin regimen with the addition of irinotecan 
180 mg/m2 as a 90-minute infusion on day 1. B was 
administered as a 30- to 90-minute intravenous infusion 
at a dose of 5 mg/kg on day 1 of each 2-week cycle. 
Treatment was to be continued until disease progression 
(PD), withdrawal of consent or unacceptable toxicity, 
whichever came first. Tumor assessment tests were 
performed within 28 days of the start of the study treatment 
and repeated every 8 weeks during treatment until PD.
Response Evaluation Criteria in Solid Tumors 
(RECIST) guidelines were used to define all responses. An 
independent central review of patient scans was not carried 
out. Adverse events were graded according to the National 
Cancer Institute Common Toxicity Criteria (NCI-CTC) 
for Adverse Events, Version 3. We considered both deep 
vein thrombosis and pulmonary embolism for VTE. 
Thrombosis caused by infusion devices was excluded.
The study was performed in accordance with 
the principles of Good Clinical Practice and the ethical 
standards of the Declaration of Helsinki. The protocol was 
approved by the local Ethics Committee for each study 
site and written informed consent was obtained from each 
patient. Participation in this study was not mandatory for 
patients enrolled in the ITACa clinical trial.
Blood collection
Samples of peripheral blood (3 ml) were collected 
from each patient at baseline and after 2 months’ treatment 
with first-line chemotherapy. After collection, serum 
was separated by centrifugation and the supernatant 
was immediately transferred into cryovials and stored at 
–80°C.
hs-CRP assay
After thawing serum samples at room temperature, 
hs-CRP was determined by particle enhanced immune-
turbidometric assay using Cobas 6000 Analyser and 
dedicated reagents (Roche, Mannheim, Germany). Anti-
CRP antibodies coupled to latex microparticles reacted 
with CRP in the sample to form an antigen/antibody 
complex. This led to agglutination and turbidity of the 
reaction mixture, which was proportional to the CRP 
concentration and measured quantitatively. The lower 
detection limit of the hs-CRP assay was 0.15 mg/L and the 
functional sensitivity 0.3 mg/L; the within-run precision 
(CV) was 1.6% at 0.54 mg/L and 0.4% at 15.9 mg/L, 
while the intermediate precision was 8.4% at 0.53 mg/L 
and 2.1% at 13.3 mg/L.
Statistical analysis 
The objectives of this secondary analysis were to 
examine the association between baseline hs-PCR levels 
and PFS and OS in the ITACa population, and to investigate 
their effect on PFS and OS of the addition of B to standard 
CT in the 2 different hs-PCR subgroups. The data cut-off 
for analysis was 31st December 2013, when the median 
duration of follow-up was 36 months (range 1–65).
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PFS was defined as the time from random assignment 
to the first documentation of PD (as per investigator 
assessment), or death from any cause. Patients undergoing 
curative metastasectomy were censored at the time of 
surgery. OS was defined as the time interval between random 
assignment and death or last follow-up visit. PFS, OS and 
their two-sided 95% confidence intervals (95% CI) were 
estimated by the Kaplan-Meier method and curves were 
compared by the log-rank test (at a significance level of 5%). 
The distribution of raw serum baseline hs-CRP data 
was skewed (data not shown) but was symmetric after log 
transformation. For this reason, the log-transformed hs-
CRP level was used to observe the relationship between 
continuous hs-CRP levels and PFS and OS.
We performed ROC curve analysis to determine the 
best threshold of hs-PCR levels to predict PD at 9 months. 
Estimated hazard ratios (HRs) and their two-sided 95% CI 
were calculated using the Cox proportional-hazard model. 
HRs adjusted by baseline characteristics (gender, age, 
performance status, KRAS status, tumor localization (rectum/
colon) and chemotherapy regimen (FOLFOX4/FOLFIRI)) 
were calculated using the Cox proportional-hazard model. 
Covariate selection was based on a list of suspected 
prognostic factors derived from the ITACa study [22]. 
The effect of the interaction between hs-CRP 
levels and treatment on PFS/OS was evaluated using Cox 
regression models of the entire population (CT + B and 
CT only arms) including hs-CRP levels, treatment, and 
treatment by hs-CRP levels. We also used nonparametric 
test to examine the potential correlation between baseline/
second sample hs-CRP levels and disease progression 
or therapy regimen in 107 patients for whom sequential 
hs-CRP data were available. All p values were based on two-
sided testing. Statistical analyses were performed using SAS 
statistical software version 9.3 (SAS Inc., Cary, NC, USA).
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